Ticker: CPHI, Company: CHINA PHARMA HOLDINGS, INC., Type: 10-K, Date: 2019-03-28, XBRL Interactive Financials
Original SEC Filing: Click here

---

Webplus: CPHI/20190328/10-K/1/000.htm SEC Original: f10k2018_chinapharmahold.htm

---

---

Webplus: CPHI/20190328/10-K/2_EX-10.1/000.htm SEC Original: f10k2018ex10-1_chinapharma.htm
December 5, 2018 Dear Ms. Heung Mei Tsui On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc as a director. The compensation is $16,000 per year. I look forward to working with you. Your appointment date is December 5, 2018 with a term

---

---

Webplus: CPHI/20190328/10-K/3_EX-10.2/000.htm SEC Original: f10k2018ex10-2_chinapharma.htm
December 5, 2018 Dear Ms. Zhilin Li, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc as a director. The compensation is $16,000 per year. I look forward to working with you. Your appointment date is December 5, 2018 with a term of

---

---

Webplus: CPHI/20190328/10-K/4_EX-10.5/000.htm SEC Original: f10k2018ex10-5_chinapharma.htm
Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD98,395.27 respectively as of December 31, 2018. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui

---

---

Webplus: CPHI/20190328/10-K/5_EX-31.1/000.htm SEC Original: f10k2018ex31-1_chinapharma.htm
CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

---

---

Webplus: CPHI/20190328/10-K/6_EX-31.2/000.htm SEC Original: f10k2018ex31-2_chinapharma.htm
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,

---

---

Webplus: CPHI/20190328/10-K/7_EX-32.1/000.htm SEC Original: f10k2018ex32-1_chinapharma.htm
18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 28, 2019 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 7 f10k2018ex32-1_chinapharma.htm CERTIFICATION

---

Company Info:

Ticker: CPHI, Company: CHINA PHARMA HOLDINGS, INC., Type: 10-K, Date: 2019-03-28, XBRL Interactive FinancialsCIK: 0001106644, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
2ND FLOOR, NO. 17, JINPAN ROAD, HAIKOU
HAINAN PROVINCE 570216